Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 5.49% and Operating profit at 16.96% over the last 5 years
2
The company has declared Negative results for the last 6 consecutive quarters
3
With ROE of 20.62%, it has a expensive valuation with a 0.93 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,409 Million (Mid Cap)
5.00
NA
0.00%
0.45
20.62%
0.93
Revenue and Profits:
Net Sales:
1,784 Million
(Quarterly Results - Mar 2026)
Net Profit:
155 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.74%
0%
-3.74%
6 Months
-8.39%
0%
-8.39%
1 Year
6.01%
0%
6.01%
2 Years
0.57%
0%
0.57%
3 Years
-15.11%
0%
-15.11%
4 Years
6.36%
0%
6.36%
5 Years
-32.71%
0%
-32.71%
Qingdao Baheal Medical, INC. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.49%
EBIT Growth (5y)
16.96%
EBIT to Interest (avg)
13.38
Debt to EBITDA (avg)
0.43
Net Debt to Equity (avg)
0.39
Sales to Capital Employed (avg)
1.51
Tax Ratio
21.06%
Dividend Payout Ratio
63.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
25.95%
ROE (avg)
21.96%
Valuation key factors
Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
0.93
EV to EBIT
4.79
EV to EBITDA
4.22
EV to Capital Employed
0.95
EV to Sales
0.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
19.87%
ROE (Latest)
20.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,783.80
1,879.40
-5.09%
Operating Profit (PBDIT) excl Other Income
214.70
61.10
251.39%
Interest
28.50
26.90
5.95%
Exceptional Items
7.90
-0.80
1,087.50%
Consolidate Net Profit
155.50
11.30
1,276.11%
Operating Profit Margin (Excl OI)
120.40%
13.60%
10.68%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -5.09% vs 0.19% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 1,276.11% vs -96.76% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
7,465.60
8,061.20
-7.39%
Operating Profit (PBDIT) excl Other Income
853.70
1,072.20
-20.38%
Interest
105.80
81.90
29.18%
Exceptional Items
72.80
-7.10
1,125.35%
Consolidate Net Profit
571.90
767.00
-25.44%
Operating Profit Margin (Excl OI)
96.90%
121.60%
-2.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -7.39% vs -1.92% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -25.44% vs -0.48% in Dec 2024
About Qingdao Baheal Medical, INC. 
Qingdao Baheal Medical, INC.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






